Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Expanded Access Listings

You can search in free text – simply type the disease, drug, company name, or other detail into the Search bar below and click Apply
Displaying 430 of 454

Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

EA Page: https://www.alphamabonc.com/en/html/news/2744.html

Abbisko Therapeutics Co., Ltd.

Savara Inc.

EA Page: https://savarapharma.com/development/expanded-access-policy/

Epicrispr Biotechnologies

EA Page: https://epicrispr.com/expanded-access-policy/

StemCyte Inc.

EA Page: https://www.stemcyte.com/expandedaccesspolicy

C Ray Therapeutics (Chengdu) Co., Ltd.

EA Page: https://www.c-raytherapeutics.com/EAP

Nanjing Leads Biolabs Co., Ltd.

EA Page: https://en.leadsbiolabs.com/innovate/sympathy

David A. Williams, MD, sponsor

EA Page: https://nam02.safelinks.protection.outlook.com/?url=https%3A//gb7i0ksb.r.us-eas…

Celcuity Inc

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Conditions: Breast Neoplasm Malignant Female

Continued access to treatment for subjects who continue benefit from therapy withgedatolisib in combination with palbociclib, and fulvestrant or letrozole.

Bristol-Myers Squibb

Expanded Access for Apixaban

Conditions:

This is an expanded access designed to provide access to apixaban for eligibleparticipants.

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Page 42
  • Current page 43
  • Page 44
  • Page 45
  • Page 46
  • Next page ››
  • Last page Last »

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA